Open AccessReal-life use of ramucirumab in gastric cancer in Spain: the RAMIS study
Author(s) -
Federico Longo,
Mónica Jorge,
Ricardo Yayá,
Ana Montes,
Nieves Martínez Lago,
Elena Brozos,
Jorge Aparicio,
Guillermo Quintero,
Eduardo Cervera Ceballos,
Elvira Buxó,
Ana María López,
María Luz Pellón,
Raquel Molina,
Laura Díaz-Paniagua,
Paula Cerdà,
Pedro López Leiva,
Alfonso Martín Carnicero,
Antía Cousillas,
Lorena Paris,
Beatriz García-Paredes,
C. Romero,
María Eugenia Ortega,
A. Molero,
Sergio De La Torre,
MinHua Jen,
Silvia DíazCerezo
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1216
Subject(s) - ramucirumab , medicine , regimen , cancer , paclitaxel , retrospective cohort study , randomized controlled trial , gastroenterology , oncology
Aims: To obtain real-world data on ramucirumab use and effectiveness for the treatment of advanced gastric cancer (AGC) or gastroesophageal junction adenocarcinoma (GEJ). Methods: Observational, retrospective study carried out in 20 Spanish hospitals, in patients who started ramucirumab treatment between December 2015 and December 2018. Descriptive analysis was conducted for patient characteristics, treatment patterns and effectiveness outcomes. Results: Three hundred seventeen patients were included (93.7% treated with ramucirumab-paclitaxel and 6.3% with ramucirumab); age 62.5 (11.3) years; 66.9% male. Median progression-free survival and overall survival were 3.9 months (95% CI: 3.4–4.3) and 7.4 (95% CI: 6.4–8.9) in combination regimen and 2.0 (1.1–2.8) and 4.3 (95% CI: 1.9–7.3) in monotherapy, respectively. Conclusion: The study findings were consistent with available real-world studies and randomized clinical trials.